Pfizer (PFE) FY2012 results: revenue $54.7 billion, down 10.4% on the year
Pfizer Inc. (PFE) reported revenue of $54.7 billion for fiscal 2012, the year ended 31 December 2012, down 10.4% on the year before. Net income was $14.6 billion, up 45.6%, and diluted earnings per share $1.94. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2013.
Revenue
$54.7 billion
-10.4% on the year
FY2007FY2012
Operating margin
n/a
FY2007FY2012
Net income
$14.6 billion
+45.6% on the year
FY2007FY2012
Diluted EPS
$1.94
+52.8% on the year
FY2007FY2012
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Revenue
54,657
61,035
65,165
-10.4%
Cost of revenue
9,821
12,500
14,788
-21.4%
Gross profit
44,836
48,535
50,377
-7.6%
Gross margin
82.0%
79.5%
77.3%
Research and development
7,482
8,681
9,483
-13.8%
Selling, general and administrative
15,171
17,581
18,973
-13.7%
Interest expense
1,524
1,681
1,799
-9.3%
Pre-tax income
11,242
11,481
9,471
-2.1%
Income tax
2,221
3,621
1,153
-38.7%
Effective tax rate
19.8%
31.5%
12.2%
Net income
14,570
10,009
8,257
+45.6%
Net margin
26.7%
16.4%
12.7%
Diluted EPS
$1.94
$1.27
$1.02
+52.8%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Operating cash flow
16,746
20,240
11,454
-17.3%
Capital expenditure
1,327
1,660
1,513
-20.1%
Free cash flow
15,419
18,580
9,941
-17.0%
Free cash flow margin
28.2%
30.4%
15.3%
Cash from investing
6,154
1,843
-492
+233.9%
Cash from financing
-15,999
-20,607
-11,174
Depreciation and amortisation
7,394
8,701
8,399
-15.0%
Share-based compensation
481
419
405
+14.8%
Buybacks
8,228
9,000
1,000
-8.6%
Dividends paid
6,534
6,234
6,088
+4.8%
Dividend per share
$0.88
$0.80
$0.72
+10.0%
Diluted shares, weighted
7,508m
7,870m
8,074m
-4.6%
Balance sheet
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Shareholders' equity
81,260
82,190
87,813
-1.1%
Non-controlling interest
418
431
452
-3.0%
Debt
37,460
38,942
44,013
-3.8%
Other liabilities
66,660
66,439
62,736
+0.3%
Total liabilities and equity
185,798
188,002
195,014
-1.2%
Fixed assets
13,213
14,673
17,607
-10.0%
Goodwill
43,661
44,569
43,432
-2.0%
Intangible assets
45,146
51,184
57,558
-11.8%
Investments
36,468
33,084
26,277
+10.2%
Cash and equivalents
10,081
3,182
1,735
+216.8%
Receivables
10,675
13,058
13,380
-18.2%
Inventory
6,076
6,610
8,275
-8.1%
Other assets
20,478
21,642
26,750
-5.4%
Total assets
185,798
188,002
195,014
-1.2%
10-K for the year ended 31 December 2012, filed 28 February 2013: the filing.